hrp0094p2-270 | Growth hormone and IGFs | ESPE2021
Lundberg Elena
, Renholm Petra
, Molin AEsa
, Ellerth Ebba
, Ernstsson Camilla
,
Background: Since the 1980s, growth hormone (GH) treatment has been administered to children as daily subcutaneous (SC) injections. GH-treatment is extremely costly, and requires a high level of training and education, otherwise there is a risk of a poor response to treatment by the patient. This can lead to a waste of time and money for the family. The key to good adherence and successful treatment is patient understanding of the growth/metabolic problem and ...